title: Olanzapine plus fluoxetine treatment increases Nt-3 protein levels in the rat prefrontal cortex.
abstract: Evidence is emerging for a role for neurotrophins in the treatment of mood disorders. In this study, we evaluated the effects of chronic administration of fluoxetine, olanzapine and the combination of fluoxetine/olanzapine on the brain-derived-neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophin-3 (NT-3) in the rat brain. Wistar rats received daily injections of olanzapine (3 or 6 mg/kg) and/or fluoxetine (12.5 or 25mg/kg) for 28 days, and we evaluated for BDNF, NGF and NT-3 protein levels in the prefrontal cortex, hippocampus and amygdala. Our results showed that treatment with fluoxetine and olanzapine alone or in combination did not alter BDNF in the prefrontal cortex (p=0.37), hippocampus (p=0.98) and amygdala (p=0.57) or NGF protein levels in the prefrontal cortex (p=0.72), hippocampus (p=0.23) and amygdala (p=0.64), but NT-3 protein levels were increased by olanzapine 6 mg/kg/fluoxetine 25mg/kg combination in the prefrontal cortex (p=0.03), in the hippocampus (p=0.83) and amygdala (p=0.88) NT-3 protein levels did not alter. Finally, these findings further support the hypothesis that NT-3 could be involved in the effect of treatment with antipsychotic and antidepressant combination in mood disorders.
authors.affiliation: Laboratório de Neurociências and Instituto Nacional de Ciência e Tecnologia Translacional em Medicina (INCT-TM), Programa de Pós-Graduação em Ciências da Saúde, Unidade Acadêmica de Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-000 Criciúma, SC, Brazil.
authors.forename: Fabiano R
authors.initials: FR
authors.lastname: Agostinho
authors.forename: Gislaine Z
authors.initials: GZ
authors.lastname: Réus
authors.forename: Roberto B
authors.initials: RB
authors.lastname: Stringari
authors.forename: Karine F
authors.initials: KF
authors.lastname: Ribeiro
authors.forename: Bianca
authors.initials: B
authors.lastname: Pfaffenseller
authors.forename: Laura
authors.initials: L
authors.lastname: Stertz
authors.forename: Bruna S
authors.initials: BS
authors.lastname: Panizzutti
authors.forename: Flávio
authors.initials: F
authors.lastname: Kapczinski
authors.forename: João
authors.initials: J
authors.lastname: Quevedo
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001569:Benzodiazepines / Q000494:pharmacology*; D004357:Drug Synergism; D004359:Drug Therapy, Combination / Q000379:methods; D005473:Fluoxetine / Q000494:pharmacology*; D008297:Male; D020933:Neurotrophin 3 / Q000096:biosynthesis* / Q000378:metabolism; D000077152:Olanzapine; D017397:Prefrontal Cortex / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects* / Q000502:physiology*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D005473:Fluoxetine; D020933:Neurotrophin 3; D000077152:Olanzapine; D017367:Selective Serotonin Reuptake Inhibitors